Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Posts Tagged ‘NASDAQ:CBAY’


Is CymaBay Therapeutics Inc (CBAY) Going To Burn These Hedge Funds ?

How do we determine whether CymaBay Therapeutics Inc (NASDAQ:CBAY) makes for a good investment at the moment? We analyze the sentiment of a select group......(read more)

Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc (CBAY)

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and optimism......(read more)
Jim Tananbaum - Foresite Capital

Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc (CBAY)

Does CymaBay Therapeutics Inc (NASDAQ:CBAY) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the......(read more)

Hedge Funds Are Buying CymaBay Therapeutics Inc (CBAY)

Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research......(read more)
biotech research company, bio-technology companies

13G Filing: Perceptive Advisors and Cymabay Therapeutics Inc. (CBAY)

Cymabay Therapeutics Inc. (NASDAQ:CBAY): Joseph Edelman’s Perceptive Advisors filed an amended 13D. You can check out Perceptive Advisors’......(read more)
Healthcare Careers That Require a Master’s Degree

13G Filing: Foresite Capital Fund III, L.P. and Cymabay Therapeutics Inc. (CBAY)

Cymabay Therapeutics Inc. (NASDAQ:CBAY): Jim Tananbaum’s Foresite Capital Fund III, L.P. filed an amended 13D. You can check out Foresite Capital......(read more)
dna, bio, clone, helix, medical, health, research, cell, gene, microscopic, render, tech, chemistry, molecular, liquid, life, biotechnology, technology, medicine, molecule,

Taking A Look At CymaBay Therapeutics Inc (CBAY)’s Big Deal

CymaBay Therapeutics Inc (NASDAQ:CBAY) is running up on the news that it has scored an exclusive licensing agreement with Kowa Pharmaceuticals America......(read more)
Tesla Motors Inc (NASDAQ:TSLA), Car, Model S, Sign, Showroom, Brand, Logo, automotive, sales

Here’s Why Apple, Tesla, and Three Other Stocks Are Trending

With the new investing year having just begun, plenty of meaningful events have caused major stocks such as Apple Inc. (NASDAQ:AAPL), Tesla Motors Inc......(read more)

Corporate Insiders at Alcoa Inc. (AA) and Two Other Battered Companies Keep Buying Shares

The insider buying activity in the past several weeks has been muted ahead of the first-quarter earnings season. However, aluminum producer Alcoa Inc. (......(read more)

Actuant Corporation (ATU) and 2 Other Battered Companies Receive a Vote of Confidence from Insiders

Aside from analyzing the financials of companies, which involves the analysis of their balance sheets and quarterly earnings reports, some investors also......(read more)
Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

Is CymaBay Therapeutics Inc (CBAY) A Good Stock To Buy?

Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply......(read more)

Lumber Liquidators Holdings Inc (LL): Steve Cohen’s Point72 Seems To Love This Stock

Steve Cohen’s Point72 Asset Management disclosed today a huge increase in its stake in Lumber Liquidators Holdings Inc (NYSE:LL). The funds affiliated......(read more)

Why Steve Cohen Added CymaBay Therapeutics Inc (CBAY) to His Portfolio?

CymaBay Therapeutics Inc (NASDAQ:CBAY) has been recently added to Steve Cohen‘s equity portfolio, as a new filing with the Securities and Exchange......(read more)